Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nexalin Technology, Inc.NXL · Entity 8197 | Director · Chief Medical Officer | December 19, 2025 | December 23, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nexalin Technology, Inc.
Report date December 19, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)*SEC Table II · derivative / convertible security · Conversion / exercise price $0.83 · Expires 2030-12-19 | Direct | 2,484,809 |
Reported balance
After 2025-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-12-19 · Grant · Acquired 1,000,000 · Balance 2,484,809 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 19, 2025 Filed Dec 23, 2025 14:41 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy)* · Derivative | 1,000,000 | $0.00 Strike: $0.83 | $0.00 |
DisclosureSEC source: 0001829126-25-010253 · ownership.xml · derivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,484,809 Underlying: Common Stock · 1,000,000 shares Expires 2030-12-19 Read SEC document |
| September 29, 2025 Filed Sep 30, 2025 21:01 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantCommon stock | 36,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001829126-25-007777 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 191,252 Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:08 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001829126-25-007373 · ownership.xml · derivative · entry 2 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,484,809 Underlying: Common Stock · 100,000 shares Expires 2030-08-29 Read SEC document |
| September 12, 2025 Filed Sep 12, 2025 21:08 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 203,125 | $0.00 Strike: $0.96 | $0.00 |
DisclosureSEC source: 0001829126-25-007373 · ownership.xml · derivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,384,809 Underlying: Common Stock · 203,125 shares Expires 2030-08-29 Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:33 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 125,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001829126-25-001254 · ownership.xml · derivative · entry 3 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 919,184 Underlying: Common Stock · 125,000 shares Expires 2029-12-27 Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:33 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 654,363 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001829126-25-001254 · ownership.xml · derivative · entry 2 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 794,184 Underlying: Common Stock · 654,363 shares Expires 2034-06-30 F1 · derivative.exercise_date: The option vests in three equal annual installments based on the satisfaction of certain performance criteria for each of the annual periods ending June 30, 2024, 2025 and 2026. The performance criteria for the period ending June 30, 2024 were met, resulting in the vesting of options to purchase 218,121 shares. Read SEC document |
| February 26, 2025 Filed Feb 27, 2025 21:33 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 139,821 | $0.00 Strike: $0.89 | $0.00 |
DisclosureSEC source: 0001829126-25-001254 · ownership.xml · derivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,821 Underlying: Common Stock · 139,821 shares Expires 2033-06-30 Read SEC document |
| February 04, 2025 Filed Feb 4, 2025 22:05 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $2.98 | $2,980.00 |
DisclosureSEC source: 0001829126-25-000672 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,793 Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 20:17 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $3.10 | $3,100.00 |
DisclosureSEC source: 0001829126-25-000724 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,793 Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:22 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,500 | $2.70 | $4,050.00 |
DisclosureSEC source: 0001829126-25-000542 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,793 Read SEC document |
| January 23, 2025 Filed Jan 24, 2025 21:55 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $2.70 | $2,700.00 |
DisclosureSEC source: 0001829126-25-000368 · ownership.xml · nonDerivative · entry 2 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,293 Read SEC document |
| January 13, 2025 Filed Jan 24, 2025 21:55 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 2,000 | $2.50 | $5,000.00 |
DisclosureSEC source: 0001829126-25-000368 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,293 Read SEC document |
| December 20, 2024 Filed Jan 29, 2025 22:26 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $2.75 | $2,750.00 |
DisclosureSEC source: 0001829126-25-000544 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,293 Read SEC document |
| November 07, 2024 Filed Jan 29, 2025 22:26 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | GrantStock Option (right to buy) · Derivative | 262,500 | $0.00 Strike: $0.94 | $0.00 |
DisclosureSEC source: 0001829126-25-000544 · ownership.xml · derivative · entry 2 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,500 Underlying: Common Stock · 262,500 shares Expires 2029-08-26 Read SEC document |
| October 28, 2024 Filed Oct 30, 2024 14:55 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 500 | $2.19 | $1,095.00 |
DisclosureSEC source: 0001829126-24-007091 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 148,293 Read SEC document |
| August 13, 2024 Filed Aug 15, 2024 20:25 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $0.95 | $950.00 |
DisclosureSEC source: 0001829126-24-005573 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,793 Read SEC document |
| June 28, 2024 Filed Jul 1, 2024 17:47 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $1.75 | $1,750.00 |
DisclosureSEC source: 0001829126-24-004517 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,793 Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 15:21 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,619 | $0.71 | $1,149.49 |
DisclosureSEC source: 0001829126-24-004353 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,793 Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 17:19 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 1,000 | $0.62 | $620.00 |
DisclosureSEC source: 0001829126-24-004108 · ownership.xml · nonDerivative · entry 2 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,174 Read SEC document |
| June 10, 2024 Filed Jun 12, 2024 17:19 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock | 2,000 | $0.65 | $1,300.00 |
DisclosureSEC source: 0001829126-24-004108 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,174 Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 18:05 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon Stock | 2,500 | $4.15 | $10,375.00 |
DisclosureSEC source: 0001829126-22-017005 · ownership.xml · nonDerivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,174 Read SEC document |
| September 16, 2022 Filed Oct 5, 2023 16:08 UTC | Nexalin Technology, Inc. NXL · Entity 8197 | PurchaseCommon stock warrants · Derivative | 2,500 | $0.40 Strike: $4.15 | $1,000.00 |
DisclosureSEC source: 0001829126-23-006449 · ownership.xml · derivative · entry 1 Owens David · CIK 0001916664 · Director · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 2,500 shares Expires 2025-09-19 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.